PAUL A FRIEDMAN
CIK 1236927 · Chief Executive Officer · last filed 2026-06-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$505.81M
Companies
10
Total Filings
126
Lifetime Open-Market Net
-$322.93M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PRLD | Director | 500,098 | $4.68 | $2.34M | $0 | 7 | 2026-06-10 |
| MDGL | Director | 865,744 | $540.18 | $467.66M | -$146.42M | 24 | 2026-01-13 |
| INCY | Director | 271,813 | $131.75 | $35.81M | -$175.53M | 41 | 2020-05-28 |
| Dare Bioscience, Inc. (CERU) Delisted | Director | 1,882 | — | — | $0 | 6 | 2017-04-05 |
| VSTM | Director | 250 | $6.22 | $1.6K | $24.9K | 3 | 2016-06-16 |
| MADRIGAL PHARMACEUTICALS, INC. (SNTA) Delisted | Director | 5,681 | — | — | $0 | 3 | 2015-07-06 |
| AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | Director | 5,000 | — | — | -$1.00M | 23 | 2015-01-30 |
| Durata Therapeutics, Inc. (DRTX) Delisted | Director | — | — | — | $0 | 1 | 2013-05-20 |
| Sirtris Pharmaceuticals, Inc. (SIRT) Delisted | Director | — | — | — | $0 | 1 | 2008-04-18 |
| BAUSCH & LOMB INC (BOL) Delisted | Director | 2,286 | — | — | $0 | 1 | 2007-09-25 |
Recent Filings · Page 2 of 13
126 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-07-22 | MDGL | Mixed | — | -$476.8K | EDGAR |
| 2025-07-18 | MDGL | Notice (144) | −1,400 | -$488.2K | EDGAR |
| 2025-07-18 | MDGL | Mixed | — | -$9.93M | EDGAR |
| 2025-07-17 | MDGL | Notice (144) | −2,700 | -$931.4K | EDGAR |
| 2025-07-16 | MDGL | Notice (144) | −26,176 | -$8.14M | EDGAR |
| 2025-06-24 | MDGL | Grant (A) | +715 | $0 | EDGAR |
| 2025-06-13 | PRLD | Grant (A) | — | $0 | EDGAR |
| 2024-06-27 | MDGL | Grant (A) | +714 | $0 | EDGAR |
| 2024-06-18 | PRLD | Grant (A) | — | $0 | EDGAR |
| 2024-04-10 | MDGL | Mixed | — | -$6.22M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.